Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Johnson and Johnson
AstraZeneca
UBS
Cantor Fitzgerald

Generated: August 19, 2019

DrugPatentWatch Database Preview

Patent: 7,674,470

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,674,470
Title:Recombinant toxin fragments
Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain H.sub.N portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated H.sub.C thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds. Antibodies that bind to the polypeptides, and compositions comprising these antibodies, are also provided, as are DNA vaccines comprising polynucleotides that encode these polypeptides. The antigenic and antibody compositions, and the DNA vaccine compositions, can be used in methods of immunising against, or treating, clostridial neurotoxin poisoning in a subject by administering to that subject a therapeutically effective amount of the composition.
Inventor(s): Shone; Charles Clifford (Salisbury, GB), Quinn; Conrad Padraig (Lilburn, GA), Foster; Keith Alan (Salisbury, GB), Chaddock; John (Salisbury, GB), Marks; Philip (Salisbury, GB), Sutton; J. Mark (Salisbury, GB), Stancombe; Patrick (Salisbury, GB), Wayne; Jonathan (Salisbury, GB)
Assignee: Health Protection Agency (Salisbury, GB) Syntaxin Limited (Salisbury, GB)
Application Number:11/077,550
Patent Claims:see list of patent claims

Details for Patent 7,674,470

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Try a Free Trial Health Protection Agency (Salisbury, GB) Syntaxin Limited (Salisbury, GB) 2016-08-23 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Citi
Fish and Richardson
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.